TheStreet Ratings

10 Best Life Sciences Stocks for 2016 - Top Stocks - TheStreet Ratings

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 life sciences stocks are rated highest by our methodology.

Equity Top: Life Sciences Tools & Services


Source: TheStreet Ratings

Best Investments for

Life Sciences

Doug Kass shares his thoughts on Twitter and talks about Sears.
3/27/17 1:00AM
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
3/26/17 2:00PM
Chairman Michael Ferro's decision to buy out Oaktree Capital sent the publisher's stock higher on Friday even as it begged the question whether other shareholders might want a similar deal.
3/24/17 5:00PM
Last year, the Indianapolis-based pharmaceutical company's U.S. capital investments were $750M, according to spokesman Greg Kueterman.
3/24/17 3:12PM
Investors weren't completely distracted by the Affordable Care Act debate.
3/24/17 9:37AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
3/24/17 8:34AM
These big stocks are teetering on the edge of breakdown territory.
3/24/17 7:55AM
The biotech company will either pick up assets to grow or sell itself to a larger company in the space, its chief financial officer told a conference.
3/23/17 7:07PM
Stocks fall on Thursday afternoon after House leaders delay a highly anticipated vote on the Republicans' repeal-and-replace health care bill.
3/23/17 3:44PM
Flexion is an arthritis-focused biotech company.
3/23/17 11:25AM
Anyone can give their pet a treat or the occasional grooming, but room service, a hotel room of their own or immortality?
3/23/17 11:01AM
CEO Joseph Papa takes home approximately $62.7 million yearly.
3/23/17 10:49AM
Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
3/23/17 9:36AM
Valeant shares were down nearly 2% at one point on news that it has completed several refinancing transactions.
3/22/17 6:33PM
In the first quarter of the year we've seen some high-profile IPOs. But they're not all created equal. Here's what investors should keep an eye out for ... and avoid.
3/22/17 3:45PM